Ex Vivo Hematoma Thrombolysis With Modified rtPA for ICH

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, cross-sectional study using ex vivo models of intracerebral hematomas created from whole blood. It compares clot dissolution after catheter-based delivery of a modified rtPA in samples from adults with and without hemorrhagic risk factors, including antithrombotic use and inherited bleeding disorders. The goal is to understand how such risk factors may affect clot breakdown in a controlled, laboratory setting. No in vivo testing in patients is performed; the work is conducted on ex vivo hematoma models to inform potential therapeutic approaches. The investigation is led by University Hospital, Lille, with sites at CHU de Lille, and involves a single additional blood collection per participant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult participants (≥ 18 years of age)
* Able and willing to provide written informed consent
* Receiving routine outpatient care
* Either:
* Without identified hemorrhagic risk (control subjects)
* With a predefined hemorrhagic risk profile, including antithrombotic treatment, inherited bleeding disorders, thrombocytopenia or conditions requiring reversal or correction of coagulation abnormalities
* Able to undergo a single additional whole blood collection (30 mL) during a routine clinical visit

Exclusion Criteria:

* Age \< 18 years
* Inability or unwillingness to provide written informed consent
* Contraindication to venipuncture or blood sampling
* Known human immunodeficiency virus (HIV) infection
* Breastfeeding
* Presence of an additional coagulation abnormality not related to the identified hereditary bleeding disorder or the antithrombotic treatment under study
* Individuals deprived of liberty by judicial or administrative decision
* Individuals under legal protection (guardianship or curatorship)

Where it's running

• CHU de Lille
  Lille, France Recruiting

Study contacts

• Principal investigator: Mélanie Daniel, MD — University Hospital, Lille
• Study coordinator: Mélanie DANIEL, MD
• Email: melanie.daniel@chu-lille.fr
• Phone: +33 3 20 44 48 42

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries

  Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.

  Recruiting Columbia University · Miami, Florida and 8 other locations · NCT07917728

• Chinese multicenter group studies spontaneous intracerebral hemorrhage in adults

  This study tests how a large group of adults with spontaneous intracerebral hemorrhage (and a healthy control group) progress over time to understand outcomes and determinants of recovery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07833410

• Rapid Evacuation and Access of Cerebral Hemorrhage Registry: observing minimally invasive surgery outcomes

  This registry collection tests how minimally invasive brain-bleed procedures work in real patients with acute spontaneous intracerebral hemorrhage.

  Recruiting Emory University · Atlanta, Georgia · NCT07651631

• Single triple-combination blood pressure pill after intracerebral hemorrhage

  This trial tests whether a single pill combining amlodipine, valsartan, and hydrochlorothiazide helps adults who recently had an intracerebral hemorrhage control their blood pressure.

  Recruiting The University of Hong Kong · Hong Kong, Hong Kong and 3 other locations · NCT07458880

• Vitamin D treatment after intracerebral hemorrhage

  This will try giving higher-dose vitamin D to adults within 96 hours of an intracerebral hemorrhage to see if it helps clear the bleed faster and is safe.

  Recruiting The University of Hong Kong · Hong Kong · NCT07458815

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.